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of proteinuria, decline in renal function, or any 
combination of the above. Most often, the symp‑
toms develop during or after nasopharyngeal in‑
fection. Currently, only the kidney biopsy allows 
to diagnose IgAN. Treatment and follow‑up are 
based mainly on the thorough assessment of very 
nonspecific factors such as proteinuria, creati‑
nine levels, and glomerular filtration rate (GFR). 
Therefore, more sensitive tools that could facili‑
tate a faster and safer diagnosis of IgAN and that 
INTRODUCTION IgA nephropathy (IgAN) is 
the most common primary glomerulonephritis. 
The disease usually occurs between the 2nd and 
4th decade of life, predominantly in men. It is 
genetically‑associated and, in less than 10% of 
the cases, also family‑related.1,2 Additionally, there 
are geographical differences in genetic suscepti‑
bility to IgAN.3
Usually, the first pathological symptoms are ei‑
ther erytrocyturia or hematuria, different degrees 
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ABSTRACT
INTRODUCTION IgA nephropathy (IgAN) is the most common primary glomerulonephritis. The first symp‑
toms of IgAN are erytrocyturia or hematuria, proteinuria, and decline in renal function, or any combination 
of the above. One of the promising diagnostic methods is urine proteomics.
OBJECTIVES We studied urine proteomics in patients with IgAN and age‑ and sex‑matched healthy 
controls. To minimize the risk of protein degradation, we proposed a new protocol for urine collection 
and preparation.
PATIENTS AND METHODS A total of 30 patients with IgAN and 30 controls were enrolled into the study. 
Thirty urine samples of the IgAN group were divided into 3 disease pooled samples (DPS I, II, and III) and 
30 urine samples of the control group were divided into 3 control pooled samples (CPS I, II, and III). We 
used isoelectric focusing/liquid chromatography–mass spectrometry/mass spectrometry (IEF/LC‑MS/MS) 
to detect all proteins larger than 10 kDa.
RESULTS Using qualitative analysis, we identified 761, 951, and 956 proteins in each of the 3 IEF/LC‑MS/MS 
experiments. The results were combined, yielding a dataset with 1238 proteins identified by at least 
2 peptides. The statistical analysis of the quantitative results  revealed 18 proteins that were differently 
populated in the urine of IgAN patients compared with healthy controls. We found increased urinary 
concentrations of complement components, coagulation factors, extracellular matrix, intracellular, trans‑
membrane, and other proteins in patients with IgAN. Some of them have never been linked to IgAN before.
CONCLUSIONS We demonstrated that urine proteomics is a promising tool for diagnosing and monitor‑
ing patients with IgAN.
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Urine collection Samples were collected from 
all individuals according to a uniform study pro‑
tocol, following the recommendations on urine 
proteomic sample collection.8 The second‑ or 
third‑morning midstream urine was collected 
to sterile urine containers 1 to 3 h after previous 
urination. The pH of each sample was stabilized 
at 7.2 by addition of 1/10th vol. of 1M HEPES pH 
7.2 immediately after collection. Then, samples 
were vortexed for 2 min, centrifuged at 3000 × g 
at room temperature for 10 min to clear the de‑
bris, filtered (0.4‑µm filter, Rotilabo‑Spritzenfil‑
ter, Roth, Karlsruhe, Germany), and portioned 
into 1‑ml aliquots that were stored at –80°C be‑
fore further use.
Sample filtration Membrane filters of the 10 kDa 
cut‑off (Amicon Ultra‑0.5, UFC501 096, Millipore, 
Billerica, United States) were washed twice with 
MilliQ (MQ) water prior to use. Urine was cen‑
trifuged through the membrane at 14,000 × g for 
15 min. Next, 500 µl MQ was added to the re‑
tentate and centrifugation step was repeated. 
To recover the concentrated and desalted sam‑
ple, the filter was placed upside down and centri‑
fuged in a clean microcentrifuge tube for 2 min 
at 1000 × g. The protein concentration was mea‑
sured by the Bradford method. Aliquots of sam‑
ples were stored at –80°C.
Sample preparation, study design, and mass spec-
trometry settings The study design is illustrated 
in Supplementary material online, FIGURE S1. Sam‑
ple preparation, pooling, labeling, and MS mea‑
surements were performed as described else‑
where.9 Shortly, 30 IgAN samples were divided 
into 3 disease pooled samples (DPSs I, II, and 
III), and similarly, 30 control samples were divid‑
ed into 3 control pooled samples (CPSs I, II, and 
III). Age and sex matching was preserved with‑
in the 3 pairs of pooled sample groups. All DPSs 
and CPSs were obtained in 2 technical replicates 
(marked A and B) each, making a set of 12 pooled 
samples to be compared after isobaric tags for rel‑
ative and absolute quantitation (iTRAQ) labeling. 
As 4‑plex iTRAQ was used, 2 technical replications 
of DPSs and CPSs were compared in 1 isoelectric 
focusing/liquid chromatography–mass spectrom‑
etry/mass spectrometry (IEF/LC‑MS/MS) ex‑
periment. To analyze 12 samples, we conduct‑
ed a set of 3 independent IEF/LC‑MS/MS exper‑
iments. Aliquots with extracted peptides were 
stored at –80°C for the IEF/LC‑MS/MS analysis.
Mass spectrometry: qualitative MS/MS data pro-
cessing The MS/MS data were pre‑processed 
with Mascot Distiller (v. 2.3.2.0, Matrix Science, 
London, United Kingdom). Data search using 
the MASCOT search engine was conducted on 
the Swiss‑Prot database with the taxonomy re‑
stricted to Homo sapiens (20,236 sequences) in 
a 3‑step procedure described elsewhere to calcu‑
late MS and MS/MS measurement errors and to 
recalibrate the data for the repeated MASCOT 
could be a good indicator of treatment response 
are still being sought.
It was previously reported that the presence 
of urinary proteins is indicative of glomerular 
damage and interstitial fibrosis. Therefore, one 
of the most promising diagnostic tools is urine 
proteomics, particularly because the biological 
material can be obtained easily and comes di‑
rectly from the diseased organ, the kidney. Dur‑
ing the last decade, several valuable studies have 
linked proteomics to IgAN, and a number of urine 
proteins considered IgAN‑specific have been re‑
ported.4,5 However, the quality of the final results 
was limited by differences in the methodology of 
urine collection, the number of patients and con‑
trol subjects studied, and their proteinuria and 
GFR values. Those factors could considerably con‑
found data interpretation in the previous studies.
The aim of our research was to study urine 
proteomics in patients with IgAN in compari‑
son with age‑ and sex‑matched healthy controls. 
Considering the challenges in methodology used 
in other studies,4,5 we proposed a new protocol 
for urine collection and preparation. The key aim 
was to limit the risk of protein degradation. First, 
all samples were collected from the second‑ or 
third‑morning midstream urine, 1 to 3 h after 
previous urination. Second, as the presence of 
low‑molecular‑weight (LMW) proteinuria in IgAN 
indicated a less favorable outcome with high‑
er incidence of chronic renal failure (47%) com‑
pared with those patients who did not have LMW 
proteinuria (10%); therefore, we also searched 
short peptides (≥2).6 To the best of our knowl‑
edge, this has been  the first report of IgAN urine 
proteomics profiling performed according to this 
protocol. As a result, we have defined several new 
proteins that are unique for patients with IgAN.
PATIENTS AND METHODS Groups of patients 
The study included 30 patients with IgAN and 
30 healthy age‑ and sex‑matched volunteers serv‑
ing as controls. Demographic and clinical data of 
both groups are presented in Supplementary ma-
terial online, TABLE S1. Patients with biopsy‑proven 
IgAN at different stages of chronic kidney dis‑
ease (CKD) and older than 18 years were includ‑
ed. The inclusion criteria for the control group 
were as follows: age older than 18 years and ab‑
sence of any kidney disease or other chronic dis‑
eases requiring treatment. The exclusion criteria 
for both groups included: active infection, histo‑
ry of malignancy, previous organ transplantation, 
or current pregnancy. To estimate GFR, we used 
the Chronic Kidney Disease Epidemiology Collab‑
oration equations, which are the most accurate, 
have been evaluated in large diverse populations, 
and are applicable for clinical use.7 The study pro‑
tocol was approved by the local ethics committee 
and informed consent was obtained from all par‑
ticipants. The study was performed in accordance 
with the Declaration of Helsinki.
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to remove systematic bias. Protein ratios were 
calculated as the median ratio of their peptide’s 
ratios. The statistical significance of a single pro‑
tein ratio was assessed by an in‑house program, 
Diffprot.12 Calculated P values were adjusted for 
multiple testing using a false discovery rate‑con‑
trolling procedure, yielding protein ratio q values.
Protein network analysis The proteins identified 
in our study were searched in the STRING data‑
base version 9.1 for protein–protein interactions.13
RESULTS Data on kidney function in both 
groups are presented in Supplementary material 
online, TABLE S1. Of 30 patients with IgAN, 15 were 
treated with angiotensin‑converting enzyme in‑
hibitors and 19 with immunosuppression, main‑
ly oral steroids. The number of patients at differ‑
ent stages of CKD were as follows: 10 patients in 
stage 1, 6 in stage 2, 10 in stage 3, and 4 in stage 4.
A set of 30 IgAN samples was divided into 
3 subsets, containing 10 samples each, which were 
then pooled into 3 DPSs: I, II, and III. Similarly, 
control set was divided into 3 CPSs: I, II, and III, 
retaining age and sex matching within the sub‑
sets. In addition, 2 technical replicates of each 
DPS or CPS were prepared, further denoted A or 
B to assess the intragroup technical variability.
As a result of qualitative analysis (peptide 
and protein identification) in each of the  3 
IEF/LC‑MS‑MS/MS experiments, 761, 951, and 
956 proteins were identified, respectively, each 
represented by 2 or more peptides (Supplemen-
tary material online, TABLE S2). One‑peptide hits 
were not taken into account in subsequent quan‑
titative analysis.
Qualitative results (protein lists) from 
3 IEF/LC‑MS‑MS/MS experiments were com‑
bined, resulting in a dataset with all 1238 pro‑
teins identified by at least 2 peptides. Within this 
dataset, identified proteins were again grouped 
based on identical peptide sets and each group 
was treated as a single protein cluster in further 
processing. After quantitative analysis, the fi‑
nal combined protein list accepted for quantita‑
tion contained 1176 proteins. However, 627 of 
these proteins were common for all replicates of 
the experiment.
The statistical analysis of the quantitative re‑
sults of the 3 IEF/LC‑MS/MS experiments re‑
vealed 18 proteins that were differently populated 
(with P <0.05) in the urine of patients with IgAN 
as compared with healthy controls. The differen‑
tial protein list is presented in Supplementary ma-
terial online, TABLE S3.14-37 The differences in pro‑
tein levels (protein ratio) can be substantial; in 
some cases, the levels may be even 5‑fold higher. 
Among DPSs, 2 were downregulated and 16 were 
upregulated in patients with IgAN.
All proteins identified in our study were 
searched in the STRING database, which defines 
a metric called “confidence score” to describe in‑
teraction confidence. We fetched all interactions 
for our dataset, which had a medium confidence 
search.10 The initial search parameters were set as 
follows: enzyme, semi‑trypsin; fixed modification, 
cysteine modification by MMTS; iTRAQ labeling 
of lysine side chains and the N‑terminus of pep‑
tides; variable modifications, oxidation; missed 
cleavages, 1. For the repeated search, the recal‑
ibrated data from all gel sections were merged 
into 1 input file and searched using MASCOT 
against the Swiss‑Prot database supplemented 
with the decoy database to obtain the statistical 
assessment of the identification of each peptide 
by a joined target/decoy database search strate‑
gy.11 This procedure provided q value estimates for 
each peptide spectrum match (PSM) in the data‑
set. All PSMs with q values exceeding 0.01 were 
removed from further analysis. A protein was re‑
garded as reliably identified if at least 2 peptides 
originating from this protein were found. Proteins 
identified by a subset of peptides from anoth‑
er protein were excluded from the analysis. Pro‑
teins that exactly matched the same set of pep‑
tides were clustered into 1 group/cluster (FIGURE 1). 
The MS/MS spectra of peptides fulfilling the ac‑
ceptance criteria were subjected to quantitative 
analysis to obtain a list of proteins differentially 
populated between a set of 3 DPSs and 3 CPSs.
iTRAQ quantitative analysis For protein quanti‑
tation, only unique peptides (i.e., peptides be‑
longing only to 1 protein/cluster) were included. 
In the first step, using the MascotDistiller pro‑
gram, iTRAQ reporter ion peaks were detected 
in the preprocessed MS/MS spectra; next, their 
intensities were corrected for isotope impurity 
using the information provided by the reagent 
manufacturer. For each spectrum, a geometric 
mean of 2 reporter ion intensities belonging to 
1 study group (DPSs or CPSs) was separately cal‑
culated. A ratio of these mean values (CPS mean 
divided by DPS mean) was reported as the pep‑
tide ratio. If more than 1 spectrum was obtained 
for a peptide in a single IEF/LC‑MS/MS exper‑
iment, the median peptide ratio value from all 
spectra was used. Prior to the protein ratio calcu‑
lations, peptide ratios were median‑normalized 
IgAN I IgAN II
IgAN III
57
37
40
627
125
162
127
FIGURE 1 Results of 
qualitative analysis: a 
Venn diagram 
representing the number 
of proteins identified by 2 
or more peptides in 3 
biological replicates of the 
isobaric tags for relative 
and absolute quantitation 
experiment (3 isoelectric 
focusing gel strips); 627 
proteins are common in 
all 3 experiments 
Abbreviations: IgAN – IgA 
nephropathy
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extracellular matrix, intracellular, transmem‑
brane, and other proteins. Some of them have 
never been linked to IgAN before. Additional‑
ly, the results were consistent with urine pro‑
teomics of patients with renal failure in the course 
of autosomal dominant polycystic kidney dis‑
ease (ADPKD), described elsewhere.9 Considering 
the pathophysiology of this disease, this is an im‑
portant assessment because urinary proteins in 
ADPKD differ from those in glomerulopathies.42
There is evidence that the complement sys‑
tem plays a critical role in the pathogenesis of 
IgAN.43-49 It is known that C3 glomerular depo‑
sition is detected in more than 90% of patients 
with IgAN, which indirectly proves that comple‑
ment activation is involved in glomerular dam‑
age in IgAN.43 Moreover, dimeric and polymer‑
ic IgA have been found to activate the comple‑
ment system in the glomeruli via alternative or 
lectin pathways, thus leading to glomerular dam‑
age.44,45 On the other hand, mesangial C3 deposi‑
tion is an independent risk factor for IgAN pro‑
gression.46 In any event, the activation of C3 and 
C3 convertase production is the key cause of his‑
tological damage induced following the formation 
of the membrane attack complex (C5b‑9).47 There‑
fore, it would be important for the future studies 
of urine proteomics in IgAN to distinguish extra‑ 
from intraglomerular C3 component. Also, an in‑
creased serum level of complement components 
for, e.g., factor H, properdin, and regulatory pro‑
teins, has been reported in IgAN.48 The concen‑
trations of activated C3 were elevated in 30% of 
the patients with IgAN and correlated positively 
with hematuria.49
One can argue that the administration of an‑
giotensin‑converting enzyme inhibitor, angioten‑
sin II receptor antagonists, antiplatelet drugs, or 
score of 0.4 and higher. The resulting interac‑
tome had 13 nodes and 34 interactions (FIGURE 2).
DISCUSSION The aim of the study was to evalu‑
ate urine proteomics of patients with IgAN. For 
the purpose of this experiment, patients with 
stable renal function, assessed by the serum cre‑
atinine concentration, GFR level, and daily pro‑
teinuria excretion, were selected and compared 
with healthy volunteers. We found specific pro‑
teins that were identified only in the IgAN cohort 
as compared with the control group. What differ‑
entiates our study from others is that we inves‑
tigated also short proteins (≥2 peptides). Some‑
times they are estimated to be produced in large 
amounts by proteolysis of large proteins. There‑
fore, their examination could be a novel way to 
establish IgAN biomarkers. The analysis of short 
peptides in the serum from patients with IgAN 
were previously reported.38 For decades, nephrol‑
ogists have searched for diagnostic methods that 
would be repetitive, sufficiently sensitive, safe 
(especially compared with renal biopsy), and that 
would enable continuous monitoring and strat‑
ifying risk for progression of the disease, partic‑
ularly in the ambulatory care.39-41 It would seem 
that nephrologists are in the privileged situation 
because the primary biological material that we 
usually assess—the urine—comes almost direct‑
ly from the affected organ. Therefore, its skilful 
evaluation should allow us to establish a prompt 
and accurate diagnosis. Consequently, many peo‑
ple believe that proteomic studies of the urine 
have great potential to be used both in the diag‑
nosis and evaluation of kidney disease activity, 
especially of glomerulonephritis.
We found increased urinary concentrations of 
complement components, coagulation factors, 
FIGURE 2 Network 
topology of the protein– 
–protein interactions of 
our protein dataset as 
extracted from the 
STRING database
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steroids, all frequently used by IgAN patients in‑
cluding those in our study, may affect the com‑
plement system. However, it was reported that 
none of the above affected the serum concentra‑
tion of either fibrinogen or complement C3 frag‑
ments.38 Given the above, it seems that the simul‑
taneous assessment of certain complement com‑
ponents, both in urine and serum (rather than 
in kidney biopsy), might be useful in the evalua‑
tion of IgAN. Moreover, 8 of 18 urinary proteins 
(47%) that were increased in our study are in‑
volved in complement activation and hemosta‑
sis, including: α‑2‑macroglobulin, ceruloplasmin, 
complement C3, complement C4A, haptoglobin, 
prothrombin, and antithrombin‑III (ATIII). It is 
known that ATIII inhibits coagulation and inac‑
tivates the plasmin and complement system. All 
these facts link the complement activation path‑
ways with platelet function and plasma coagula‑
tion factors. It appears that the stability of this 
system might be critical to the development and 
progression of IgAN.
In our opinion, urine proteomics might be 
an important tool, especially at the time of diag‑
nosis and during exacerbations. In the first case, 
it may allow us to introduce an appropriate treat‑
ment, and in the second, it increases our chance 
of recognizing a relapse and prevent progression 
of IgAN. Currently, a practical approach in both 
situations involves estimation of daily protein‑
uria in combination with the serum creatinine 
concentration and the GFR change as a function 
of time. However, it is not surprising to see pa‑
tients with daily proteinuria below 0.5 g but with 
high immune activity of the disease or advanced 
kidney fibrosis in renal histopathology. Therefore, 
a more sensitive methodology with a follow‑up 
of IgAN patients is needed. This applies also to 
other glomerulopathies assessed by proteinuria. 
Additionally, we found 6 other proteins linked 
to proteolysis and 4 to cell–cell communication.
We demonstrated that the urine protein profile 
may be a useful tool to confirm IgAN in patients 
suspected of this glomerulonephritis. The limita‑
tion of our study was that we assessed proteins 
in the whole collected material. For this reason, 
we cannot indicate which protein might be a di‑
agnostic marker of the disease activity and prob‑
ably also of renal fibrosis due to IgAN. This result‑
ed from the sensitivity of the methods, the fact 
that we looked for every protein with 2 peptides 
and more, as well as from limited financial re‑
sources. Further research is needed to address 
all those issues.
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SUPPLEMENTARY MATERIAL ONLINE
TABLE S1 Demographic characteristics and renal function of the study and control 
groups
IgAN group (n = 30) Control group (n = 30)
sex, male / female 15 / 15 15 / 15 
age, y 39.8 (20–60) 39.3 (20–62)
body mass, kg 76.1 (46–135) 75.7 (45–105)
serum creatinine, μmol/l 94.5 (40.2–279.9) 120.1 (51.5–365.6)
GFR (CKD‑EPI formula), ml/min 66.3 (17.5–127.6) 99.3 (66.6–132)
proteinuria, g/d 1.19 (0–3.9) 0
Data are presented as mean (range).
Abbreviations: CKD‑EPI – Chronic Kidney Disease Epidemiology Collaboration, GFR – 
glomerular filtration rate, IgAN – IgA nephropathy
TABLE S2 Number of identified peptides and proteins in 3 replicates of the iTRAQ 
experiment on pooled samples
Replicate (IEF gel strip) Number of peptides 
(accepted PSMs)
Number of proteins 
(identified by ≥2 
peptides)
1 6300 1468 (761)
2 7398 1726 (951)
3 7874 1811 (956)
CPS I A   114
CPS I B   115
DPS I A   116
DPS I B   117
pooled sample iTRAQ label IEF/LC‑MS/MS
1
CPS II A   114
CPS II B   115
DPS II A   116
DPS II B   117
CPS III A   114
CPS III B   115
DPS III A   116
DPS III B   117
2
3
FIGURE S1 Study design; combining 12 pooled samples into 3 isoelectric focusing 
strips analyzed in 3 liquid chromatography–mass spectrometry/mass spectrometry 
(IEF/LC‑MS/MS) experiments
TABLE S3 Differential protein list; proteins of different levels in the urine of patients with IgA nephropathy (IgAN) compared with healthy controls; 
the ratio is given as IgAN/control
Symbol of 
protein
Gene ID Peptides q value Ratio Molecular functions Biological process References
AFM P43652 21 0.00007 7.71 vitamin E binding vitamin transport 14
ALB P02768 197 0.00007 7.52 DNA binding, antioxidant 
activity, chaperone binding, 
copper and zinc ion binding, 
fatty acid binding, drug and 
toxic substance binding
transport, cellular response to 
starvation, hemolysis by 
symbiont of host erythrocytes, 
maintenance of mitochondrion 
location, regulation of apoptotic 
process
15-17
APOA1 P02647 19 0.0192 2.92 cholesterol metabolism, lipid 
metabolism, lipid transport, 
steroid metabolism, sterol 
metabolism, transport, blood 
coagulation
cholesterol metabolism, lipid 
metabolism, lipid transport, 
steroid metabolism, sterol 
metabolism, transport, blood 
coagulation
18
AZGP1 P25311 47 0.00007 2.49 receptor activity B‑cell‑mediated immunity, 
antigen processing and 
presentation, cellular defense 
response
19
A2M P01023 54 0.00007 5.71 peptidase activity, cytokine 
activity, serine‑type 
endopeptidase inhibitor 
activity
complement activation, 
proteolysis, cellular process, 
response to stimulus, regulation 
of catalytic activity
20
CA1 P00915 14 0.03499 2.94 hydro‑lyase activity metabolic process 21
CP P00450 68 0.00007 4.82 oxidoreductase activity, serine‑ 
‑type peptidase activity, 
metalopeptidase activity, 
receptor activity, lipid 
transporter activity, 
transmembrane transporter 
activity, receptor binding, 
enzyme regulator activity
immune system process, 
proteolysis, synaptic 
transmission, cell–cell 
adhesion, visual perception, 
sensory perception, ectoderm 
development, mesoderm 
development, skeletal system 
development, angiogenesis, 
nervous system development, 
heart development, blood 
coagulation, lipid transport, 
intracellular protein transport, 
endocytosis, vitamin transport, 
regulation of catalytic activity
22
C3 P01024 63 0.00007 3.74 peptidase activity, cytokine 
activity, serine‑type 
endopeptidase inhibitor 
activity
complement activation, 
proteolysis, cellular process, 
response to stimulus, regulation 
of catalytic activity
23
C4A P0C0L4 61 0.00254 2.47 peptidase activity, cytokine 
activity, serine‑type 
endopeptidase inhibitor 
activity
complement activation, 
proteolysis, cellular process, 
response to stimulus, regulation 
of catalytic activity
24
FN1 P02751 65 0.01055 0.75 receptor binding cell communication, cell–matrix 
adhesion, cell–cell adhesion
25
F2 P00734 6 0.03499 6.59 serine‑type peptidase activity immune system process, 
proteolysis, blood coagulation
26
GC P02774 21 0.01001 2.95 actin binding, vitamin D binding, 
vitamin transporter activity
transport  27,28
HP P00738 21 0.00007 6.51 serine‑type peptidase activity, 
calcium ion binding, 
calmodulin binding, calcium‑
dependent phospholipid 
binding
gamete generation, complement 
activation, proteolysis, cellular 
process, blood circulation, 
response to stress, blood 
coagulation
29
IGFBP7 Q16270 11 0.02975 0.28 stimulates prostacyclin (PGI2) 
production, stimulates cell 
adhesion
cell adhesion, negative regulation 
of cell proliferation
30,31
PSAP P07602 18 0.04907 2.83 enzyme activator activity, lipid 
binding
lipid metabolism, sphingolipid 
metabolism
32
SERPINA1 P01009 109 0.00007 6.86 serine‑type peptidase activity, 
peptidase inhibitor activity
proteolysis, regulation of 
biological process, regulation of 
catalytic activity
33,34
SERPINA3 P01011 40 0.00041 2.55 serine‑type peptidase activity, 
peptidase inhibitor activity
proteolysis, regulation of 
biological process, regulation of 
catalytic activity
35
SERPINC1 P01008 21 0.00968 3.7 serine‑type peptidase activity, 
peptidase inhibitor activity
proteolysis, regulation of 
biological process, regulation of 
catalytic activity
36,37
Abbreviations: AFM – afamin, ALB – serum albumin, APOA1 – apolipoprotein A‑I, AZGP1 – zinc‑α‑2‑glycoprotein, A2M – alpha‑2‑macroglobulin, CA1 – 
carbonic anhydrase 1, CP – ceruloplasmin, C3 – complement C3, C4A – complement C4A, FN1 – fibronectin, F2 – prothrombin, GC – vitamin D‑binding 
protein, HP – haptoglobin, IGFBP7 – insulin‑like growth factor‑binding protein 7, PSAP – proactivator polypeptide, SERPINA1 – α‑1‑antitrypsin, 
SERPINA3 – α‑1‑antichymotrypsin, SERPINC1 – antithrombin‑III
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SŁOWA KLUCZOWE
afamina, fibronektyna, 
nefropatia IgA, 
proteomika, składowe 
dopełniacza
STRESZCZENIE
WPROWADZENIE Nefropatia IgA (IgAN) jest najczęstszym kłębuszkowym zapaleniem nerek. Pierwszymi 
objawami IgAN są krwinkomocz lub krwiomocz, białkomocz, pogorszenie czynności nerek lub kombinacja 
powyższych objawów. Jedną z bardziej obiecujących metod diagnostycznych jest proteomika moczu.
CELE Przeprowadzono badanie proteomiczne moczu pacjentów z IgAN oraz zdrowych ochotników do‑
branych pod względem płci i wieku. Aby zminimalizować ryzyko degradacji białek, zaproponowaliśmy 
nowy protokół zbierania i przygotowania moczu.
PACJENCI I METODY W badaniu uczestniczyło 30 pacjentów z IgAN oraz 30 ochotników. 30 próbek po‑
chodzących od pacjentów z IgAN oraz 30 próbek z grupy kontrolnej podzielono na 3 grupy (odpowiednio 
disease pooled samples – DPS I, II i III i control pooled samples – CPS I, II i III). Metodą zastosowaną 
do wykrycia białek większych niż 10 kDa była spektrometria mas sprzężona z chromatografią cieczową 
poprzedzona ogniskowaniem izoelektrycznym (IEF/LC-MS/MS).
WYNIKI Na podstawie analizy jakościowej, w każdym z 3 eksperymentów IEF/LC-MS/MS zidentyfiko‑
waliśmy odpowiednio 761, 951 i 956 białek. Połączenie tych wyników dało listę 1238 białek zidenty‑
fikowanych przez co najmniej 2 peptydy. Analiza statystyczna wyników eksperymentów ilościowych 
wykazała 18 specyficznych dla IgAN białek, w porównaniu do grupy kontrolnej. W grupie pacjentów 
z IgAN stwierdziliśmy zwiększone stężenia w moczu składników dopełniacza, czynników krzepnięcia, 
macierzy pozakomórkowej, białek wewnątrzkomórkowych oraz przezbłonowych. Niektóre z nich nigdy 
wcześniej nie były opisane w moczu chorych na IgAN.
WYNIKI Wykazaliśmy, że badanie proteomiczne moczu może być dobrym narzędziem do diagnostyki 
i monitorowania pacjentów z nefropatią IgA.
ARTYKUŁ ORYGINALNY
Składowe dopełniacza, białka proteolityczne 
oraz uczestniczące w komunikacji między 
komórkami, stwierdzane w badaniu 
proteomicznym moczu są związane 
z nefropatią IgA
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